Synthetic virology: Engineering viruses for gene delivery

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 6, Issue 6, 2014, Pages 548-558

  Guenther, Caitlin M ^a   Kuypers, Brianna E ^b   Lam, Michael T ^a   Robinson, Tawana M ^b   Zhao, Julia ^b   Suh, Junghae ^a,b  

^a Rice University   (United States)

^b RICE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; GENE THERAPY; GENE TRANSFER; NANOPARTICLES; NATURAL POLYMERS; VECTORS;

DESIGN STRATEGIES; ENGINEERED COMPONENTS; FUNCTIONAL CAPACITY; FUNCTIONAL PARTS; GENE DELIVERY VECTORS; GENETIC MATERIALS; INORGANIC NANOPARTICLE; NANOSCALE DEVICE;

VIRUSES;

NANOCARRIER; NANOPARTICLE; PARVOVIRUS VECTOR; POLYMER; VIRUS VECTOR;

ADENOVIRIDAE; CHIMERA; COMPLEX FORMATION; DNA MODIFICATION; DNA SHUFFLING; DRUG CONJUGATION; GENE INSERTION; HUMAN; MUTAGENESIS; NANOENGINEERING; NONHUMAN; PLANT VIRUS; POINT MUTATION; PRIORITY JOURNAL; PSEUDOTYPING; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL TROPISM; VIRUS CAPSID; VIRUS GENE; VIRUS HYBRID; ANIMAL; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; MOUSE; NANOMEDICINE; SYNTHETIC BIOLOGY; VIRUS;

ANIMALS; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; NANOMEDICINE; SYNTHETIC BIOLOGY; VIRUSES;

EID: 84907876259     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1287     Document Type: Review

References (72)

1. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 2012, 20:1831-1832.
2. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012, 20:699-708.
3. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011, 365:2357-2365.
4. Wimmer E, Mueller S, Tumpey TM, Taubenberger JK. Synthetic viruses: a new opportunity to understand and prevent viral disease. Nat Biotechnol 2009, 27:1163-1172.
5. Mueller S, Coleman JR, Wimmer E. Putting synthesis into biology: a viral view of genetic engineering through de novo gene and genome synthesis. Chem Biol 2009, 16:337-347.
6. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006, 14:316-327.
7. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, DiPrimio N, Nam HJ, Agbandje-McKenna M, et al. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 2010, 28:79-82.
8. Kim JW, Glasgow JN, Nakayama M, Ak F, Ugai H, Curiel DT. An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer. PLoS One 2013, 8:e55533.
9. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441:239-243.
10. Ho ML, Adler BA, Torre ML, Silberg JJ, Suh J. SCHEMA computational design of virus capsid chimeras: calibrating how genome packaging, protection, and transduction correlate with calculated structural disruption. ACS Synth Biol 2013, 2:724-733.
11. Murakami M, Ugai H, Wang MH, Belousova N, Dent P, Fisher PB, Glasgow JN, Everts M, Curiel DT. An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populations. Virology 2010, 407:196-205.
12. Judd J, Ho ML, Tiwari A, Gomez EJ, Dempsey C, Van Vliet K, Igoshin OA, Silberg JJ, Agbandje-McKenna M, Suh J. Tunable protease-activatable virus nanonodes. ACS Nano 2014, 8:4740-4746.
13. Ho ML, Judd J, Kuypers BE, Yamagami M, Wong FF, Suh J. Efficiency of protease-activatable virus nanonodes tuned through incorporation of wild-type capsid subunits. Cell Mol Bioeng 2014. doi:10.1007/s12195-014-0334-y (Special Issue on Young Innovators).
14. Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000, 74:1524-1532.
15. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 2005, 5:387-398.
16. Funke S, Maisner A, Muhlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ. Targeted cell entry of lentiviral vectors. Mol Ther 2008, 16:1427-1436.
17. Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Redmond DE Jr, et al. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 2008, 16:1252-1260.
18. Yang L, Jiang J, Drouin LM, Agbandje-McKenna M, Chen C, Qiao C, Pu D, Hu X, Wang DZ, Li J, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A 2009, 106:3946-3951.
19. Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther 2009, 17:2088-2095.
20. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, Kay MA. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008, 82:5887-5911.
21. Gray SJ, Blake BL, Criswell HE, Nicolson SC, Samulski RJ, McCown TJ. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther 2010, 18:570-578.
22. Koerber JT, Jang JH, Schaffer DV. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 2008, 16:1703-1709.
23. Powell SK, Kaloss MA, Pinkstaff A, McKee R, Burimski I, Pensiero M, Otto E, Stemmer WPC, Soong NW. Breeding of retroviruses by DNA shuffling for improved stability and processing yields. Nat Biotechnol 2000, 18:1279-1282.
24. Stemmer WPC. Rapid evolution of a protein in-vitro by DNA shuffling. Nature 1994, 370:389-391.
25. Zhao HM, Giver L, Shao ZX, Affholter JA, Arnold FH. Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat Biotechnol 1998, 16:258-261.
26. Drummond DA, Silberg JJ, Meyer MM, Wilke CO, Arnold FH. On the conservative nature of intragenic recombination. Proc Natl Acad Sci U S A 2005, 102:5380-5385.
27. Voigt CA, Martinez C, Wang ZG, Mayo SL, Arnold FH. Protein building blocks preserved by recombination. Nat Struct Biol 2002, 9:553-558.
28. Meyer MM, Silberg JJ, Voigt CA, Endelman JB, Mayo SL, Wang ZG, Arnold FH. Library analysis of SCHEMA-guided protein recombination. Protein Sci 2003, 12:1686-1693.
29. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000, 74:8635-8647.
30. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 1999, 265:274-285.
31. O'Donnell J, Taylor KA, Chapman MS. Adeno-associated virus-2 and its primary cellular receptor-Cryo-EM structure of a heparin complex. Virology 2009, 385:434-443.
32. Levy HC, Bowman VD, Govindasamy L, McKenna R, Nash K, Warrington K, Chen W, Muzyczka N, Yan X, Baker TS, et al. Heparin binding induces conformational changes in adeno-associated virus serotype 2. J Struct Biol 2009, 165:146-156.
33. Boucas J, Lux K, Huber A, Schievenbusch S, von Freyend MJ, Perabo L, Quadt-Humme S, Odenthal M, Hallek M, Buning H. Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations. J Gene Med 2009, 11:1103-1113.
34. Coughlan L, Vallath S, Saha A, Flak M, McNeish IA, Vassaux G, Marshall JF, Hart IR, Thomas GJ. In vivo retargeting of adenovirus type 5 to alpha v beta 6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J Virol 2009, 83:6416-6428.
35. Jullienne B, Vigant F, Muth E, Chaligne R, Bouquet C, Giraudier S, Perricaudet M, Benihoud K. Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid. Gene Ther 2009, 16:1405-1415.
36. Seregin SS, Aldhamen YA, Appledorn DM, Hartman ZC, Schuldt NJ, Scott J, Godbehere S, Jiang HX, Frank MM, Amalfitano A. Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood 2010, 116:1669-1677.
37. Myhre S, Henning P, Friedman M, Stahl S, Lindholm L, Magnusson MK. Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther 2009, 16:252-261.
38. Poulin KL, Lanthier RM, Smith AC, Christou C, Quiroz MR, Powell KL, O'Meara RW, Kothary R, Lorimer IA, Parks RJ. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 2010, 84:10074-10086.
39. Warrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 2004, 78:6595-6609.
40. Munch RC, Janicki H, Volker I, Rasbach A, Hallek M, Buning H, Buchholz CJ. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther 2013, 21:109-118.
41. Yang L, Bailey L, Baltimore D, Wang P. Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A 2006, 103:11479-11484.
42. Bratkovic T. Progress in phage display: evolution of the technique and its applications. Cell Mol Life Sci 2010, 67:749-767.
43. Bupp K, Roth MJ. Altering retroviral tropism using a random-display envelope library. Mol Ther 2002, 5:329-335.
44. Miura Y, Davydova J, Yamamoto M. Transductionally-retargeted infectivity selective oncolytic adenovirus with redesigned AB-loop targeting cell surface mesothelin. Mol Ther 2012, 20:S210-S211.
45. Nishimoto T, Yamamoto Y, Yoshida K, Goto N, Ohnami S, Aoki K. Development of peritoneal tumor-targeting vector by in vivo screening with a random peptide-displaying adenovirus library. PLoS One 2012, 7:e45550.
46. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, Trepel M. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003, 21:1040-1046.
47. Ying Y, Muller OJ, Goehringer C, Leuchs B, Trepel M, Katus HA, Kleinschmidt JA. Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther 2010, 17:980-990.
48. Hida K, Won SY, Di Pasquale G, Hanes J, Chiorini JA, Ostermeier M. Sites in the AAV5 capsid tolerant to deletions and tandem duplications. Arch Biochem Biophys 2010, 496:1-8.
49. Judd J, Wei F, Nguyen PQ, Tartaglia LJ, Agbandje-McKenna M, Silberg JJ, Suh J. Random insertion of mCherry into VP3 domain of adeno-associated virus yields fluorescent capsids with no loss of infectivity. Mol Ther Nucleic Acids 2012, 1:e54.
50. Koerber JT, Schaffer DV. Transposon-based mutagenesis generates diverse adeno-associated viral libraries with novel gene delivery properties. Methods Mol Biol 2008, 434:161-170.
51. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006, 24:198-204.
52. Perabo L, Endell J, King S, Lux K, Goldnau D, Hallek M, Buning H. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J Gene Med 2006, 8:155-162.
53. Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer DV. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther 2012, 20:329-338.
54. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, Schaffer DV. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013, 5:189ra76.
55. Pulicherla N, Shen S, Yadav S, Debbink K, Govindasamy L, Agbandje-McKenna M, Asokan A. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther 2011, 19:1070-1078.
56. Lesch HP, Kaikkonen MU, Pikkarainen JT, Yla-Herttuala S. Avidin-biotin technology in targeted therapy. Expert Opin Drug Deliv 2010, 7:551-564.
57. Arnold GS, Sasser AK, Stachler MD, Bartlett JS. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther 2006, 14:97-106.
58. Morizono K, Xie YM, Helguera G, Daniels TR, Lane TF, Penichet ML, Chen ISY. A versatile targeting system with lentiviral vectors bearing the biotin-adaptor peptide. J Gene Med 2009, 11:655-663.
59. Stachler MD, Chen I, Ting AY, Bartlett JS. Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol Ther 2008, 16:1467-1473.
60. Liu YR, Fang Y, Zhou Y, Zandi E, Lee CL, Joo KI, Wang P. Site-specific modification of adeno-associated viruses via a genetically engineered aldehyde tag. Small 2013, 9:421-429.
61. Wei F, McConnell KI, Yu TK, Suh J. Conjugation of paclitaxel on adeno-associated virus (AAV) nanoparticles for co-delivery of genes and drugs. Eur J Pharm Sci 2012, 46:167-172.
62. Wu W, Hsiao SC, Carrico ZM, Francis MB. Genome-free viral capsids as multivalent carriers for taxol delivery. Angew Chem Int Ed Engl 2009, 48:9493-9497.
63. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010, 49:6288-6308.
64. Steinmetz NF, Manchester M. PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo. Biomacromolecules 2009, 10:784-792.
65. Lee GK, Maheshri N, Kaspar B, Schaffer DV. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng 2005, 92:24-34.
66. Hofherr SE, Mok H, Gushiken FC, Lopez JA, Barry MA. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther 2007, 18:837-848.
67. Park JW, Mok H, Park TG. Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Control Release 2010, 142:238-244.
68. Han JF, Zhao D, Zhong ZR, Zhang ZR, Gong T, Sun X. Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotechnology 2010, 21:105106-105115.
69. Vetter A, Virdi KS, Espenlaub S, Rodl W, Wagner E, Holm PS, Scheu C, Kreppel F, Spitzweg C, Ogris M. Adenoviral vectors coated with PAMAM dendrimer conjugates allow CAR independent virus uptake and targeting to the EGF receptor. Mol Pharm 2013, 10:606-618.
70. Grunwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Goke B, et al. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. J Nucl Med 2013, 54:1450-1457.
71. Joo KI, Fang Y, Liu YR, Xiao L, Gu Z, Tai A, Lee CL, Tang Y, Wang P. Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates. ACS Nano 2011, 5:3523-3535.
72. Huang XL, Bronstein LM, Retrum J, Dufort C, Tsvetkova I, Aniagyei S, Stein B, Stucky G, McKenna B, Remmes N, et al. Self-assembled virus-like particles with magnetic cores. Nano Lett 2007, 7:2407-2416.